RVRCOTCPharmaceutical PreparationsFiscal year ends December 31

Revium Rx.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$1.43+0.00 (0.00%)

Close on Oct 16, 2026

Market cap: $86.84M
P/E (TTM): –
Dividend yield: –

Revium Rx. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31
Cash & Equivalents	0.84	0.92	1.68	3.65	3.91	3.27
Cash & Short-Term Investments	0.84	0.92	1.68	3.65	3.91	3.27
Other Current Assets	0.34	0.33	0.38	–	–	0.24
Total Current Assets	1.86	2.48	3.10	–	–	5.52
Property, Plant & Equipment	0.01	0.01	0.01	–	–	0.01
Operating Lease Right-of-Use Assets	0.17	0.19	0.12	–	–	–
Goodwill	2.58	2.58	2.58	–	–	11
Intangible Assets	2.50	2.50	2.50	–	–	3.34
Total Assets	7.11	7.76	8.30	–	–	20
Accounts Payable	0.62	0.23	0.16	–	–	0.14
Accrued Expenses	–	–	0.46	–	–	0.15
Current Portion of Leases	0.08	0.08	0.06	–	–	–
Total Current Liabilities	0.97	1.53	0.80	–	–	0.58
Long-Term Leases	0.04	0.07	0.05	–	–	–
Operating Lease Liabilities	0.13	0.15	0.11	–	–	–
Total Liabilities	1.59	1.60	1.42	–	–	0.58
Common Stock	0.06	0.06	0.06	–	–	0.06
Additional Paid-In Capital	32	32	32	–	–	30
Retained Earnings	-26	-26	-25	–	–	-12
Shareholders' Equity	5.52	6.16	6.88	–	–	–
Noncontrolling Interest	–	–	–	–	–	0.77
Total Equity	5.52	6.16	6.88	19	19	20
Total Liabilities & Equity	7.11	7.76	8.30	–	–	20
Shares Outstanding(shares)	61	61	61	–	–	61

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 1.91
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 86.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 15.74
Dividend yield: –